Nasdaq:US$15.42 (-0.39) | HKEX:HK$25.35 (+0.85) | AIM:£2.26 (+0)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors